There’s plenty of oil supply, says markets pro
The “Futures Now” team, Scott Nations and Jim Iuorio, discuss the wild day for crude oil after Trump denied Iran’s claim U.S. offered to remove sanctions with CNBC”s Rahel Solomon.
Similar Posts
Pivoting to ‘Green New Deal’ investments will be tough for Berkshire: Analyst
ShareShare Article via FacebookShare Article via TwitterShare Article via LinkedInShare Article via Email Catherine Seifert of CFRA discusses the likelihood of Berkshire Hathaway pivoting to ‘Green New Deal’ investments under a Biden presidency. 02:02 Sun, Nov 8 202010:50 PM EST
Trader lays out the next key catalysts for bitcoin
ShareShare Article via FacebookShare Article via TwitterShare Article via LinkedInShare Article via Email Key catalysts for bitcoin, with CNBC’s Seema Mody and the Futures Now traders, Jim Iuorio and Scott Nations, both at the CME. 02:48 Tue, Sep 24 20191:57 PM EDT
Don’t confuse a bond yield rally with an earnings recovery rally, says Piper Sandler’s Kantrowitz
ShareShare Article via FacebookShare Article via TwitterShare Article via LinkedInShare Article via Email Power Lunch Michael Kantrowitz, chief investment strategist at Piper Sandler, joins ‘Power Lunch’ to discuss why he’s still bearish on the market and more. 03:33 10 minutes ago
Rep. French Hill on bitcoin ETF approval: We need a change in the ‘regulatory posture’ in Washington
House Financial Services Committee vice chairman and Digital Assets Committee chairman Rep. French Hill (R-Ark.) joins ‘Squawk Box’ to discuss the SEC’s approval of spot bitcoin ETFs, what it means for crypto regulation in Congress, and more.
Jim Cramer evaluates if the Las Vegas Sphere is worth a buy
Jim Cramer at the NYSE with Mad Money graphic, June 30, 2022. Virginia Sherwood | CNBC CNBC’s Jim Cramer has his eye on Sphere Entertainment, the company that owns the 580,000 square foot Sphere that looms in the Las Vegas skyline, but he is not recommending it to investors. “The stock’s certainly been a solid…
Ultragenyx CEO talks the company’s path to profitability in developing drugs for rare diseases
ShareShare Article via FacebookShare Article via TwitterShare Article via LinkedInShare Article via Email Dr. Emil Kakkis, Ultragenyx founder & CEO, joins ‘Closing Bell Overtime’ to talk drug trials and development, its path to profitability and more.
